Home › Funds › Atle Fund Management AB › MIRM

Atle Fund Management AB position in MIRM

MIRUM PHARMACEUTICALS INC · Health Care

Atle Fund Management AB reported holding 70,071 shares of MIRM (MIRUM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$6.0M, representing 1.60% of its reported portfolio and ranking #23 among its reported holdings. Atle Fund Management AB has disclosed MIRM holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

Latest position (Q3 2026)70.07K sh
Reported value held$5.99M
Portfolio Weight1.60%
First reportedQ1 2024
Last changeReduce
Updated2026-11-12

Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR

How Atle Fund Management AB's MIRM position evolved

Atle Fund Management AB first disclosed a stake in MIRM in Q1 2024 at 123,000 shares (US$3.1M). The position peaked in Q2 2026 at 100,807 shares, worth US$11.8M. Across 11 filings, Atle Fund Management AB increased the stake 3 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 70,071 shares valued at US$6.0M — a reduction of -30,736 shares quarter over quarter.. Notable position changes include a 84% increase in Q3 2024 (shares rose 6% over the following quarter), a 118% increase in Q1 2026 (shares rose 27% over the following quarter), a 49% trim in Q2 2026 (shares fell 27% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 123.00K $3.09M New
Q2 2024 75.20K $2.57M Reduce
Q3 2024 138.32K $5.39M Add
Q4 2024 116.69K $4.81M Reduce
Q1 2025 77.26K $3.48M Reduce
Q2 2025 106.91K $5.44M Add
Q3 2025 93.61K $728.52K Reduce
Q4 2025 89.69K $7.08M Reduce
Q1 2026 195.77K $9.40M Add
Q2 2026 100.81K $11.80M Reduce
Q3 2026 70.07K $5.99M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MIRM and 13F data

MIRM (MIRUM PHARMACEUTICALS INC) is a Health Care company. 61 other funds we track also report a position in MIRM — the largest reported positions include Frazier Life Sciences Management, L.P. (US$899.1M), EVENTIDE ASSET MANAGEMENT, LLC (US$146.2M), TANG CAPITAL MANAGEMENT LLC (US$144.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MIRM

All MIRM fund holders →

FAQ

How long has Atle Fund Management AB held MIRM?

Atle Fund Management AB has disclosed MIRM holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

What is Atle Fund Management AB's current position in MIRM?

As of Q3 2026, Atle Fund Management AB holds 70.07K shares of MIRM (MIRUM PHARMACEUTICALS INC), valued at $5.99M, representing 1.60% of its reported portfolio and ranking #23.

Has Atle Fund Management AB been buying or selling MIRM?

In the latest 13F filing (Q3 2026), Atle Fund Management AB reduced its position in MIRM. The position peaked in Q2 2026 at 100.81K shares.

Which other funds hold MIRM?

Other major institutional holders of MIRM include Frazier Life Sciences Management, L.P., EVENTIDE ASSET MANAGEMENT, LLC, TANG CAPITAL MANAGEMENT LLC, among 61 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.